Joe Rogan Experience #1964 - Rick Doblin

In MAPS’ phase 3 trials, about 88% of participants responded and 67% no longer met PTSD criteria after three MDMA‑assisted sessions plus psychotherapy, with strong safety data. This positions MDMA as a potentially transformative treatment pending FDA approval, likely around 2024 if all goes well.

Doblin describes ibogaine’s ability to alleviate opioid withdrawal and open weeks of elevated neuroplasticity, as well as his own intense ibogaine experience that severed the link between self‑criticism and self‑hatred. Despite low abuse potential, ibogaine remains Schedule I in the U.S., driving vulnerable people to unregulated foreign clinics.

Both men describe DMT and 5‑MeO‑DMT as encounters with a “source code” reality that strip away ideological armor and identity stories. Doblin stresses that the medicine alone isn’t enough: structured preparation and integration are crucial for translating breakthroughs into durable life changes.

Doblin argues drugs are neither inherently good nor bad; outcomes depend on set, setting, dose, and social context. Criminalization magnifies harm by pushing supply into unsafe markets (e.g., fentanyl contamination) and stigmatizing people who most need treatment and honest information.

Support from veterans, right‑leaning politicians (e.g., Rick Perry), and historically anti‑drug figures (e.g., Ted Nugent) has helped move psychedelics out of the culture war frame. Doblin emphasizes “being the bridge” and finding common ground, even with donors or ideologies he opposes in other arenas.

They recount the fabricated “holes in the brain” imagery promoted on MTV and Oprah, and a retracted Science paper where primates were mistakenly given methamphetamine instead of MDMA. These episodes show how funding incentives and sensationalism can override accuracy, reinforcing Doblin’s insistence on honesty about both benefits and risks.

To finish FDA approval and reach financial sustainability, MAPS needs tens of millions of dollars and is weighing large‑scale philanthropy against taking private or public investment. Going public could enable massive scale but risks profit‑pressure distorting access, pricing, and research priorities for medicines Doblin considers sacred.